[1] |
ZHU Xinzhe, LI Hao, XU Huaxiang, LUO Guopei, YU Xianjun.
Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021
[J]. China Oncology, 2022, 32(1): 1-12.
|
[2] |
YANG Shipeng , LIU Ying , WANG Xinyue , YANG Yang , QUAN Jishu , LIN Zhenhua .
Clinical significance of PKLR overexpression in the pancreatic cancer
[J]. China Oncology, 2021, 31(8): 704-713.
|
[3] |
TANG Rong, SHI Si, ZHANG Bo, XU Jin, WANG Wei, YU Xianjun.
Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2020
[J]. China Oncology, 2021, 31(1): 1-10.
|
[4] |
YAN Fang, YING Mingzhen, CHEN Longpei, FU Qiang.
Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients
[J]. China Oncology, 2020, 30(8): 632-635.
|
[5] |
ZHANG Xiaomeng , MA Ningyi , ZHU Hongcheng , AI Dashan , REN Zhigang .
Efficacy and prognostic factors of adjuvant radiotherapy combined with chemotherapy in patients with pancreatic cancer
[J]. China Oncology, 2020, 30(7): 519-524.
|
[6] |
MAO Tiebo, CUI Jiujie, WANG Liwei.
Research progress in pancreatic cancer in 2019 from experimental study to clinical evaluation
[J]. China Oncology, 2020, 30(2): 81-89.
|
[7] |
NING Zhouyu, HUA Yongqiang, XU Litao, ZHUANG Liping, FENG Lanyun, CHEN Hao, WANG Peng, SHEN Yehua, LIN Junhua, CHEN Zhen, MENG Zhiqiang.
Efficacy and safety of nab-paclitaxel plus gemcitabine in the treatment of advanced pancreatic cancer by transcatheter arterial chemotherapy: a retrospective study
[J]. China Oncology, 2020, 30(2): 128-134.
|
[8] |
PAN Zeyan, ZHAN Xianbao.
Current status and future strategies of chimeric antigen receptor T-cells in the treatment of pancreatic cancer
[J]. China Oncology, 2019, 29(7): 481-485.
|
[9] |
ZHU Xuqin,JIA Songlin,QI Jie,SHEN Xuefang,LONG Jiang,MIAO Changhong .
Perioperative factors associated with prognosis of patients after radical resection of pancreatic cancer: a retrospective analysis
[J]. China Oncology, 2019, 29(7): 521-527.
|
[10] |
JIAO Zhikai, FENG Ningning, ZHANG Yueshan, KANG Xi, YANG Baoming, LI Jiankun, CAO Heng, DONG Biao, FU Jionghui, WANG Shunxiang.
Expression of miR-762 in pancreatic cancer and its effect on biological behavior of pancreatic cancer cells
[J]. China Oncology, 2019, 29(11): 869-874.
|
[11] |
YANG Chao, LUO Guopei, LIU Chen, et al.
Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2018
[J]. China Oncology, 2019, 29(1): 1-8.
|
[12] |
GAO Qi, GUO Yan, WEI Xiaojuan.
The inhibitory effects of celastrol on proliferation, invasion and migration of human pancreatic cancer cell line PANC-1
[J]. China Oncology, 2019, 29(1): 26-31.
|
[13] |
XU Fengling, HUANG Xianyu, WANG Linna.
The effects of secretory clusterin on oxidative damage in MIA PaCa-2 cells treated by gemcitabine and preliminary mechanism of resistance to gemcitabine
[J]. China Oncology, 2018, 28(2): 111-116.
|
[14] |
ZHANG Shirong, JIN Wei, LIU Liang, et al.
Recent advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2017
[J]. China Oncology, 2018, 28(1): 1-10.
|
[15] |
LIANG Dingkong, SHI Si, XU Jin, et al.
Recent advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2016
[J]. China Oncology, 2017, 27(4): 241-250.
|